Validity of the depressive dimension extracted from principal component analysis of the PANSS in drug-free patients with schizophrenia

Yazaji, M. El; Battas, Omar; Agoub, Mohamed; Moussaoui, Driss; Gutknecht, Christian; Daléry, J; d’Amato, Thierry; Saoud, Mohamed

doi:10.1016/s0920-9964(01)00247-x

Cited by 69 publications

(46 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Factor analyses conducted with PANSS data consistently extracted the depression component in this disease [Kay and Sevy, 1990;Lindenmayer et al, 1994;Lancon et al, 2000;Lykouras et al, 2000;Wolthaus et al, 2000;El Yazaji et al, 2002]. Not all schizophrenic patients exhibit depressive symptoms Fig.…”

Section: Resultsmentioning

confidence: 79%

Serotonin transporter polymorphism and depressive‐related symptoms in schizophrenia

Голимбет

Алфимова

Shchebatykh

et al. 2003

American J of Med Genetics Pt B

View full text Add to dashboard Cite

A role for the serotonin transporter (5-HTT) gene polymorphism in mental illnesses and anxiety-traits has been implicated. The contribution of genetic factors in personality traits and the manifestation of specific symptoms in psychiatric illnesses have yet to be elucidated. Anxious-depressive symptoms are a significant component in a pattern of schizophrenic symptoms. This study focused on the relation between 5-HTT polymorphism and clinical presentations of schizophrenia, specifically those related to the affective spectrum. Using clinical and psychological analyses, we tested the genetic association between the 5-HTTLPR polymorphism (5-HTT gene-linked polymorphic region) and anxiety- and depressive-related symptoms emerged in schizophrenia. In 260 patients with an ICD-10 diagnosis of schizophrenia (broad definition), we studied the 5-HTTLPR genotype (insertion-deletion polymorphism), the Positive and Negative Syndrome Scale (PANSS), and self-rated inventories (EPI, MMPI, STAI) scores. Patients with the "ss" genotype (deletion variant) scored significantly higher on "Guilt feelings" and "Depression" items, as compared with those of the "ll" genotype (insertion variant) (P = 0.016, 0.039, respectively). The frequency of the "ss" genotype was reduced in patients with no depression or guilt feelings, or in those patients exhibiting questionable symptoms. In contrast, the "ss" genotype carriers prevailed among the patients with mild, moderate, or severe ratings of the symptoms. The scores on all anxiety- and depression-related traits, self-rated by the patients, did not significantly differ by genotype. Our finding may contribute to understanding of molecular genetic features underlying an appearance of psychopathological symptoms emerged in schizophrenia.

show abstract

Section: Resultsmentioning

confidence: 79%

Serotonin transporter polymorphism and depressive‐related symptoms in schizophrenia

Голимбет

Алфимова

Shchebatykh

et al. 2003

American J of Med Genetics Pt B

View full text Add to dashboard Cite

show abstract

“…Conversely, this method limits the rater's subjectivity. On the other hand, one can hypothesize that analysing of other proneness scales would permit the discrimination of other factors seen in schizophrenia like anxiety/depression or impulsivity/excitation [12]. Finally, as previously reported [17], our sample could be divided into three groups according to cannabis use typology: those who had never used cannabis (n = 126), those who were past or occasional users (n = 65), and those who were regular users (n = 41).…”

Section: Discussionmentioning

confidence: 99%

“…Another strategy consists in the study of psychotic-like traits in the general population [3][4][5] through the development of schizotypy and psychosis-proneness scales [6][7][8] stemmed from the idea that traits which may predispose to schizophrenia can be identified in non-clinical populations [9]. However, schizophrenia itself can no longer be viewed as a unitary construct; rather there is a growing consensus that the clinical symptoms seem to cluster into at least three distinct syndromes [10][11][12]. In turn, schiz--otypy in non clinical samples has been shown to have a similar dimensional structure, with factors resembling at least 3 dimensions of schizophrenia: positive, negative, and cognitive-disorganisation [3,4,13].…”

Section: Introductionmentioning

confidence: 99%

Three-Factor structure of self-report schizotypal traits in a French nonclinical sample

Dumas¹,

Saoud²,

d’Amato³

et al. 2011

OJPsych

Self Cite

View full text Add to dashboard Cite

Evidence suggests that the structure of psychosisproneness in the general population may involve three distinct related dimensions. Therefore we conducted a study, using a wider range of measures, to explore the factorial structure of schizotypy assessed by a mixed self-report Schizotypal Traits Questionnaire (mSTQ) in young French healthy individuals. Raine's Schizotypal Personality Questionnaire [SPQ] and four of the Chapman's scales [Magical IdeationScale-MIS; Perceptual Aberration Scale-PAS; Revised Physical Anhedonia Scale-PhA and Revised Social Anhedonia Scale-SA] were combined to form a mSTQ which was administered to 232 French undergraduate students aged from 18 to 25 years old. A Principal Component Analysis [PCA] was carried out on scores for each scale to examine the factorial structure of schizotypal traits in this sample. PCA evidenced a three-factor model of schizotypy in the sample as a whole and even in the lower score subsample. The three factors were "positive or cognitiveperceptual", "negative or social-interpersonal" and "disorganization" latent. Schizotypy, as assessed by these scales, is a multidimensional construct composed by at least three dimensions in this nonclinical sample. This factorial structure is similar to those of schizophrenia symptoms which raise the hypothesis of a continuum from normality to schizophrenia via schizotypal traits

show abstract

“…A cutoff point of eight is considered to be a definite indicator of comorbid depression. [7][8][9][10][11][12][13][14][15] Previous contrast studies have demonstrated that CDSS is able to distinguish depression from negative psychotic symptoms as well as e xt ra -p y r a mi d a l s y m p t o ms .…”

Section: Methodsmentioning

confidence: 99%

“…7 Face-to-face comparisons with other assessment tools indicated superiority of CDSS in detecting depression as well as discriminating depressive symptoms from negative symptoms of schizophrenia and extra-pyramidal side effects (EPS) of antipsychotic drugs as well. [7][8][9][10][11][12][13][14][15] The foremost aim of the current investigation was to assess the rate of depression among patients with schizophrenia visiting the psychiatric unit of Hawler Teaching Hospital (current Hawler Mental Hospital). Additionally, demographic variables were addressed in order to disclose any possible difference(s) between patients with and without depressive disorders.…”

Section: Introductionmentioning

confidence: 99%

Rate of depression among patients with schizophrenia

Rahim

2016

ZJMS

View full text Add to dashboard Cite

show abstract

Validity of the depressive dimension extracted from principal component analysis of the PANSS in drug-free patients with schizophrenia

Cited by 69 publications

References 28 publications

Serotonin transporter polymorphism and depressive‐related symptoms in schizophrenia

Serotonin transporter polymorphism and depressive‐related symptoms in schizophrenia

Three-Factor structure of self-report schizotypal traits in a French nonclinical sample

Rate of depression among patients with schizophrenia

Contact Info

Product

Resources

About